Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies
Terisse A. Brocato, Ursa Brown-Glaberman, Zhihui Wang, Reed G. Selwyn, Colin M. Wilson, Edward F. Wyckoff, Lesley C. Lomo, Jennifer L. Saline, Anupama Hooda-Nehra, Renata Pasqualini, Wadih Arap, C. Jeffrey Brinker, Vittorio Cristini
Terisse A. Brocato, Ursa Brown-Glaberman, Zhihui Wang, Reed G. Selwyn, Colin M. Wilson, Edward F. Wyckoff, Lesley C. Lomo, Jennifer L. Saline, Anupama Hooda-Nehra, Renata Pasqualini, Wadih Arap, C. Jeffrey Brinker, Vittorio Cristini
View: Text | PDF
Resource and Technical Advance Oncology

Predicting breast cancer response to neoadjuvant chemotherapy based on tumor vascular features in needle biopsies

  • Text
  • PDF
Abstract

In clinical breast cancer intervention, selection of the optimal treatment protocol based on predictive biomarkers remains an elusive goal. Here, we present a modeling tool to predict the likelihood of breast cancer response to neoadjuvant chemotherapy using patient-specific tumor vasculature biomarkers. A semiautomated analysis was implemented and performed on 3990 histological images from 48 patients, with 10–208 images analyzed for each patient. We applied a histology-based mathematical model to 30 resected primary breast cancer tumors and then evaluated a cohort of 18 patients undergoing neoadjuvant chemotherapy, collecting pre- and posttreatment pathology specimens and MRI data. We found that core biopsy samples can be used with acceptable accuracy to determine histological parameters representative of the whole tissue region. Analysis of model histology parameters obtained from tumor vasculature measurements, specifically diffusion distance divided by the radius of the drug-delivering blood vessel (L/rb) and blood volume fraction (BVF), provides a statistically significant separation of patients obtaining a pathologic complete response (pCR) from those who do not. With this model, it is feasible to evaluate primary breast tumor vasculature biomarkers in a patient-specific manner, thereby allowing a precision approach to breast cancer treatment.

Authors

Terisse A. Brocato, Ursa Brown-Glaberman, Zhihui Wang, Reed G. Selwyn, Colin M. Wilson, Edward F. Wyckoff, Lesley C. Lomo, Jennifer L. Saline, Anupama Hooda-Nehra, Renata Pasqualini, Wadih Arap, C. Jeffrey Brinker, Vittorio Cristini

×

Figure 2

Model analysis.

Options: View larger image (or click on image) Download as PowerPoint
Model analysis.
fkill values were determined as (i) calculated from meas...
fkill values were determined as (i) calculated from measured values (points; cohort A: measured from resected whole-tumor histology, cohort B: measured from needle biopsy) and (ii) model best-fit (Equation 1) line to the full data set (black line). Cohort A: 30 patients underwent primary surgery without prior systemic therapy; data were analyzed by using histology semiautomated analysis and the mathematical model. Cohort B: 18 patients receiving neoadjuvant chemotherapy; data are shown to distinguish patients with pathologic complete response (pCR) versus those without pCR. Each point is fkill calculated for an individual patient by using averages of BVF, rb, and L measured directly from tumor tissue stained with CD34 by immunohistochemistry. The black line shows fkill calculated from Equation 1 with optimized parameter L/rb = 13.6981 (determined from fitting, r2 = 0.79875). The fkill regression line includes fitting of both cohort A and cohort B patients (n = 48). Error bars are calculated based on error in BVF measurements and the respective variation that it causes when incorporated into the fkill equation (Equation 1). Correlation analysis of measured fkill and computed fkill for all 48 patients is shown in Supplemental Figure 2.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts